Signs that Amgen was cooling on rocatinlimab emerged last year. Asked about the market positioning of the antibody at a Citi ...

AstraZeneca is handing $1.2 billion in upfront cash to CSPC Pharmaceuticals for the ex-China rights to the biopharma’s ...

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for approval, contradicting the biotech’s claims that the candidate’s eventual ...

As for Chia Tai Feng Hai, the company is owned by parent company Sino Biopharmaceutical, a large Chinese pharma based in Hong ...

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. | Moderna’s Chief Medical Officer Jacqueline Miller, M.D., is stepping down after ...

AI has been hailed as a way to speed up historically sluggish drug development, but an entirely AI-designed drug has yet to be approved by the FDA. The furthest along is likely Insilico Medicine’s ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...